Arcus Biosciences
RCUS
157 hedge funds and large institutions have $1.6B invested in Arcus Biosciences in 2022 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 44 increasing their positions, 55 reducing their positions, and 19 closing their positions.
111% more call options, than puts
Call options by funds: $23.4M | Put options by funds: $11.1M
79% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 19
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
11% more funds holding
Funds holding: 142 → 157 (+15)
1.11% less ownership
Funds ownership: 72.35% → 71.25% (-1.1%)
20% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 55
22% less capital invested
Capital invested by funds: $2.06B → $1.6B (-$457M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$34.4M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$30.6M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$18.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$18.7M |
| 5 |
PA
Perceptive Advisors
New York
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$75.7M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$48.4M |
| 3 |
Morgan Stanley
New York
|
-$39.7M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$15M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$14.3M |
RCUS Hedge Fund Activity: Q1 2022 in Review
157 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2022, worth a combined $1.6B — down 22% from $2.06B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new RCUS positions and 19 closed out — a net gain of 15 holders — while 44 added to existing stakes and 55 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $34.4M. The largest seller was EcoR1 Capital, cutting an estimated $75.7M.
- 157 institutional investors held Arcus Biosciences (RCUS) as of Q1 2022, up from 142 in Q4 2021.
- Funds reported $1.6B of Arcus Biosciences stock for Q1 2022, down 22% quarter-over-quarter.
- 34 funds opened new Arcus Biosciences positions in Q1 2022 and 19 closed out, a net change of +15 holders.
- The largest Arcus Biosciences buyer in Q1 2022 was AllianceBernstein, an estimated $34.4M added.
- The largest Arcus Biosciences seller in Q1 2022 was EcoR1 Capital, an estimated $75.7M sold.
Based on aggregated 13F filings for Q1 2022.